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Low vitamin D levels have been found in patients with autoimmune diseases, including type I
diabetes, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. The main
source of vitamin D is exposure to sunlight, but the same solar radiation is known to exac-
erbate lupus erythematosus. We investigated the prevalence of vitamin D insufficiency in
patients with cutaneous lupus erythematosus (CLE). We designed a cross-sectional study
including 55 patients with CLE to measure their serum 25-hydroxyvitamin D (25(OH)D) by
chemiluminescence immunoassay and compare it with a control group consisting of 37 healthy
sex and age-matched subjects recruited from the patients’ relatives as well as healthcare work-
ers. Correlations with clinical and demographic variables were determined. Approximately
95% of patients with CLE had less than 30ng/ml of serum 25(OH)D, which is accepted as the
lower limit for vitamin D adequacy. Mean serum vitamin D values were significantly lower
than controls (p¼0.038) and were associated with higher levels of parathyroid hormone
(p¼0.050). A history of CLE was a strong predictor of insufficiency of vitamin D (odds
ratio 4.2; 95% confidence interval 1.0–17.4). The results suggest a role of CLE in the metab-
olism of the vitamin and provide guidance for future studies looking at a potential role for
vitamin D in the prevention and treatment of CLE. Lupus (2010) 19, 810–814.
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Introduction
Vitamin D is synthesized in human skin exposed
to UV radiation.
1 A lesser amount is obtained
from food, although dietary sources supply less
than 20% of the body’s requirement.
2 Vitamin D
requires a ﬁrst hydroxylation in the liver to 25-
hydroxyvitamin D (25(OH)D), which is used to
determine vitamin D status, and then another
hydroxylation in the kidney to its active form,
1-25-dihydroxyvitamin D3 (1,25(OH)2D).
Deﬁnition of vitamin D insuﬃciency has changed
over the past few years from less than 10ng/ml to
40ng/ml.
3 Presumably, optimal levels will increase
to 60ng/ml as new functions are attributed to
vitamin D.
4 Concentrations of vitamin D are inﬂu-
enced by several factors such as diet, latitude,
season, time spent outdoors, skin pigmentation,
clothing, tanning habits and supplementation.
1
Vitamin D has progressively become recognized
as a pluripotent regulator of biological functions
beyond its classical eﬀects on bone and calcium
homeostasis. The discovery that most tissues and
cells in the body have a vitamin D receptor and
the enzymatic machinery to activate 25(OH)D has
improved our understanding of other non-classical
eﬀects of this vitamin.
1 Of great interest is the role
it can play in decreasing the risk of common can-
cers such as breast, colorectal and prostate cancer.
5
Furthermore, evidence from large prospective stu-
dies in patients with rheumatoid arthritis,
6 multiple
sclerosis
7 and type 1 diabetes
8 suggest an important
role for vitamin D as a modiﬁable environmental
factor in autoimmune diseases. A high prevalence
of vitamin D insuﬃciency and deﬁciency has been
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(SLE).
9–13. The link between vitamin D deﬁciency
and CLE has not been as widely studied: previous
studies found a high prevalence of vitamin D deﬁ-
ciency in patients with CLE, although they
included patients with extracutaneous manifesta-
tions of lupus.
14,15 Here, we test the hypothesis
that inadequate levels of vitamin D are commonly
found in patients with exclusive cutaneous manifes-
tations of lupus erythematosus. Further, we will try
to identify the clinical and analytical variables asso-
ciated with vitamin D insuﬃciency as well as the
potential relationship with severity of the disease.
Materials and methods
Patients
A cross-sectional study included patients with
exclusively speciﬁc cutaneous manifestations of
lupus erythematosus, whether chronic or subacute,
attending a dermatology outpatient clinic in a
public university hospital from May to October
2008. Patients with acute CLE were excluded
owing to the strong association with SLE. Both
patients and controls lived in Valencia, a city in
southern Europe at 39  north 0  west, 11m above
sea level, with 65% average summer relative humid-
ity, an annual precipitation rate of 454mm, and
many sunny days all year round. Only patients
with more than a 1-year history of CLE, according
to clinical, analytical and histological ﬁndings,
16
were enrolled in the study. Patients who fulﬁlled at
least four of the ACR criteria for the classiﬁcation
of SLE and those with extracutaneous manifesta-
tions of the disease were excluded from the study.
CLE patients were compared with a control group
consisting of 37 healthy sex and age-matched sub-
jects (in two year bands) who were recruited from
patients’ relatives as well as healthcare workers.
To participate in the study, patients and controls
had to sign an informed consent, according to the
Declaration of Helsinki. The local institutional
review board approved the study protocol (study
code CEIC 20/09).
Methods
At enrolment, all participants were asked to com-
plete a questionnaire covering age, gender, meno-
pause, Fitzpatrick skin phototype, weight, height,
photosensitivity, use of sunscreen, usual daily sun
exposure including work activities, if currently a
smoker, and number of cigarettes per day. Details of
previous or current ongoing diseases, duration of
lupus, type of cutaneous lupus, drugs and calcium
and vitamin D supplements were obtained from
their medical history. The daily average intake of
vitamin D was estimated by measuring the
amount of vitamin D-rich food eaten in a normal
week. Assessment of CLE activity was based on the
maximum number of exacerbations and days with
active cutaneous lesions during the previous year,
according to their medical history and interview.
Within a month of the inclusion of patients
blood tests were performed: 25(OH)D, calcium,
phosphorus, complement, antinuclear antibodies
and intact parathyroid hormone (PTH). PTH and
25(OH)D were determined by chemiluminescence
immunoassay. According to current recommenda-
tions,
9,10,17 serum 25(OH)D levels <30ng/ml and
<10ng/ml were deﬁned as vitamin D insuﬃciency
and deﬁciency, respectively.
Statistical analysis
Age and levels of vitamin D in patients and con-
trols were compared. All continuous variables, age
and vitamin D were evaluated for normality of dis-
tribution, and only vitamin D in patients showed a
skewed distribution. The data were expressed as
mean standard deviation (SD) and were analysed
by analysis of variance (ANOVA) test. A  
2 test
was conducted to evaluate diﬀerences in percentage
in the other dichotomic or categorical variables.
Pearson’s correlation coeﬃcients were calculated
to describe the bivariate correlation among vari-
ables. Logistic regression models and odds ratio
(OR) were also performed with deﬁciency of vita-
min D, using a cut-oﬀ of 23.8 (mean of control
group) as the outcome variable. For statistical
inference, a bilateral p-value <0.05 was considered
statistically signiﬁcant. All analyses were calculated
using the Statistical Package for Social Science
(version 15, Chicago, Illinois, USA) for Windows.
Results
Demographic and lupus-related variables
Fifty-ﬁve patients were included in the study:
the patients’ proﬁle is summarized in Table 1.
Most patients had CLE (80%), with a mean dura-
tion of 8.2 years since diagnosis was made.
Photosensitivity was present in 69% of men and
59% of women. Sixty-seven per cent of patients
presented at least one outbreak of cutaneous
lesions during the previous year. The average
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Lupusnumber of exacerbations was 2.7 3.7 and the
mean period with active lesions was 108 14.2
days. Eight patients (14%) were taking hydroxy-
chloroquine and three women were receiving treat-
ment with vitamin D+calcium supplements. None
of the patients were receiving treatment with immu-
nosuppressive drugs. The average calculated daily
intake of vitamin D was 5.4 2.2mg. Forty-eight
patients (87%) applied sunscreen to all uncovered
skin, but only 30 (54%) used it every day assuring
optimal protection during the middle hours of the
day. Most of these patients used 50 or higher sun
protection factor. UVexposure was less than
30min/day in 20% of patients, whereas another
20% spent more than 2h/day outside.
Prevalence of vitamin D deficiency
The overall mean (SD) 25(OH)D level was
20.0 8.9ng/ml in patients and 23.8 7.5ng/ml
in controls. Diﬀerences between vitamin D levels
in patients and controls were statistically signiﬁcant
and remained so after adjustment for age (p¼0.03).
CLE was the strongest predictor of insuﬃciency of
vitamin D (OR 4.2; 95% conﬁdence interval (CI)
1.0–17.4). 25(OH)D levels decreased in older cases
(r¼ 0.21), but this did not reach statistical signif-
icance (p¼0.12). However, this trend was not seen
in controls (r¼0.13). Prevalence of vitamin D
insuﬃciency and deﬁciency in cases and controls
are shown in Figure 1. Higher levels of PTH were
associated with lower serum levels of 25(OH)D
(r¼ 0.27; p¼0.05), but no statistical signiﬁcance
was seen in controls.
We looked at other disease characteristics in
association with 25(OH)D inadequacy but no
other characteristic was found to be statistically
signiﬁcant in patients with a history of more than
10 years of lupus (p¼0.59), fair skin (p¼0.77),
smoking (p¼0.56), photosensitivity (p¼0.39),
Table 1 Patients’ profile
Gender
Males 13
(23.6%)
Females 42
(76.4%) p-value
Age (years)
Median 49.7 46.9
Standard deviation 11.8 13.9 0.52
Range: minimum–maximum 35–77 23–84
over 50 years 7 (53.8%) 17 (40.5%)
over 60 years 2 (15.4%) 7 (16.7%) 0.39
0.74
Skin type
Type II 1 (7.7%) 17 (40.5%) 0.06
Type III 9 (69.2%) 13 (31.0%) 0.01
Type IV 3 (23.1%) 12 (28.6%) 0.97
Body mass index
<24.9 6 (46.2%) 24 (57.1%) 0.48
25.0–29.0 6 (46.2%) 9 (21.4%) 0.16
>30.0 1 (7.7%) 9 (21.4%) 0.47
Cigarette smoking
Non-smokers 3 (23.1%) 16 (38.1%) 0.50
Smokers 10 (76.9%) 26 (61.9%) 0.50
Number of cigarettes a day
(mean standard deviation)
15.5 12.5 10.5 11.3 0.17
Chronic renal disease 0 (0.0%) 1(1.8 %) –
Chronic hepatic disease 2 (3.6%) 0 (0.0%) –
Chronic cardiac disease 0 (0.0%) 1 (1.8%) –
Menopause 16 (38.2%) –
Duration of menopause
<1 0 –8–
>1 0 –8–
Daily intake of vitamin D
<3.9 6 (46.2%) 9 (21.4%) 0.16
3.9–6.7 5 (38.5%) 22 (52.4%) 0.38
>6.7 2 (15.4%) 11 (26.2%) 0.66
Vitamin D levels
(mean standard deviation)
19.67 7.70 20.17 9.36 0.67
Vitamin D supplements – 3 (7.1%) –
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Lupusdetectable autoantibodies (p¼0.79), more than 180
days with active lesions within the last year
(p¼0.38), and more than 2h of outdoor exposure
(p¼0.59). As shown in Table 2, treatment with
hydroxychloroquine (OR 7.9; 95% CI 0.9–8.8) pre-
dicted vitamin D deﬁciency, whereas supplements
of vitamin D were associated with higher vitamin D
levels (p¼0.11).
Discussion
We found signiﬁcantly lower serum 25(OH)D levels
among patients with CLE compared with matched
controls and a high overall prevalence of vitamin D
insuﬃciency (<30ng/ml) and deﬁciency (<10ng/ml).
Insuﬃciency was seen in this population from
Spain in the ﬁnal spring, summer and early
autumn months, the period of highest sun expo-
sure, even in those patients with CLE who do not
follow recommendations for sunscreen use or
appropriate daily intake of vitamin D. We have
found lower mean serum levels of vitamin D in
Caucasian patients with SLE in South Carolina
10
and Texas,
18 probably due to the lower latitude, but
similar levels to other studies performed in Spain.
9
Mean serum levels of vitamin D in controls were
also lower than controls in South Carolina.
10 Our
results are in line with other recent research on vita-
min D levels in CLE that was performed in
Germany.
14 However, Cusack et al.
15 observed
a lower prevalence of vitamin D inadequacy
in Ireland, at higher latitudes, which could
be explained by the wider use of supplements of
vitamin D (40% versus 5%).
Although the sample size is larger than other
studies on vitamin D and CLE, lack of statistical
signiﬁcance in most variables could be attributed to
the large number of factors that determines the
capacity to synthesize vitamin D in the skin. This
inadequacy in vitamin D levels in patients with
CLE causes secondary hyperparathyroidism,
which further exacerbates 25(OH)D deﬁciency by
increasing its conversion to 1,25(OH)2D.
Interestingly, we found an important role for the
duration of the disease in lower 25(OH)D levels.
The inﬂuence of age in levels of vitamin D in
patients but not in controls may reﬂect the role of
the disease in the metabolism of vitamin D.
Previous studies on CLE
14 could not ﬁnd a rela-
tionship with the severity of the disease based on
indexes such as the European Consensus Lupus
Activity Measurement (ECLAM), SLEDAI or
SLICC Damaged Index (SDI), perhaps because
these scales were developed and validated speciﬁ-
cally for patients with SLE
19 and not for CLE.
Table 2 Risk of low vitamin D levels using 23.8ng/ml
(mean levels in controls) as the cut-off, in relation to different
characteristics of cutaneous lupus erythematosus
Odds ratio crude
95% confidence
interval
Age <30 1.0 (Reference)
31–40 1.0 0.2 6.5
41–50 1.5 0.2 8.9
51–60 1.5 0.2 8.9
>60 2.2 0.3 16.4
Menopause No 1.0 (Reference)
Yes 3.3 1.1 9.8
Skin type II 1.0 (Reference)
III 0.6 0.2 2.2
IV 0.6 0.2 2.2
Body mass index <24.9 1.0 (Reference)
25–29.9 0.9 0.2 2.5
>30.0 0.8 0.3 3.9
Smoking no 1.0 (Reference)
yes 0.9 0.3 3.0
Duration of disease <4 1.0 (Reference)
4–9 2.6 0.6 11.3
>9 1.3 0.3 5.3
Type of lupus Subacute 1.0 (Reference)
Chronic 1.0 0.2 4.6
Daily intake of
vitamin D
<3.9 1.0 (Reference)
3.9–6.7 1.2 0.3 4.6
>6.7 0.8 0.2 3.7
Severity <1 1.0 (Reference)
1–2 1.0 0.3–4.1
3–4 1.3 0.2–8.8
>4 3.2 0.5–19.0
Antimalarials No 1.0 (Reference)
Yes 7.9 0.9 69.8
10.9
5.4 2.7
67.6
29.7
83.6
0
10
20
30
40
50
60
70
80
90
Deficient (<10ml) Insufficient (10–30
ng/ml)
Sufficient
(>30ng/ml)
Patients
Controls
Figure 1 Prevalence of 25-hydroxyvitamin D deficiency and
insufficiency in patients and controls. Serum levels of vitamin D
of less than 30ng/ml were found in 94.5% of patients, which is
the range consistent with insufficiency, and includes six patients
(10.9%) with less than 10ng/ml. 25-hydroxyvitamin D levels in
patients were significantly lower than controls (p¼0.03).
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LupusIn view of the lack of an internationally validated
index to score CLE activity, we used a clinical
disease-related parameter, and a trend toward
lower vitamin D levels is seen in patients with
more active disease. Some studies found a negative
correlation between vitamin D levels and severity of
SLE,
2,11,18 while others
9 only found an association
between vitamin D deﬁciency and fatigue.
Interestingly, in other autoimmune disorders such
as undiﬀerentiated connective tissue disease, the
probability of developing dermatological symp-
toms correlated with vitamin D insuﬃciency.
17
Our data disclosed two apparent contradictions:
antimalarials seemed to be a predictor of lower
25(OH)D levels; hydroxychloroquine is known to
inhibit the 1a-hydroxylation of 25(OH)D, thus
decreasing the levels of 1,25(OH)2D.
9 Our results
may be due to the severity of the disease, as patients
receiving treatment with hydroxychloroquine were
those with active lesions in spite of photoprotection
and topical therapy. The ﬁnding of lower 25(OH)D
levels in patients with longer periods of active
lesions and more exacerbations during a year
would support this possibility. Nevertheless, the
low absolute number of patients who took hydro-
xychloroquine represents an additional limitation
on the interpretation of data related to this vari-
able. Further research controlling for severity of
the disease may clarify the inﬂuence of antimalar-
ials on vitamin D levels in CLE patients. The other
paradox was the ﬁnding of higher 25(OH)D levels
in darker skin, although all our patients were
Caucasians. It could be explained by the lack of
photosensitivity in patients with Fitzpatrick skin
type IV. Another confounding factor, time spent
outdoors, could be behind this ﬁnding.
Although more studies are needed to understand
the role of vitamin D as an immunomodulator, the
existence of vitamin D receptors in T and B lympho-
cytes, macrophagues and dendritic cells is well
known. Perhaps the most profound eﬀects on the
immune system are on dendritic cells,
10 modulating
their maturational state. Furthermore, 1,25(OH)2D
down-regulates dendritic cell production of
interleukin-12 and augments interleukin-10, consist-
ing of a shift towards a Th2 response. B lymphocyte
diﬀerentation is also interrupted when exposed
in vitro to vitamin D. Although increasing levels
of dietary vitamin D intake are not associated
with a decreased risk of autoimmune diseases,
12
administration of supplementary vitamin D to
mouse models of SLE resulted in a loss of dermato-
logical manifestations.
20 Based on our ﬁndings and
evidence in the literature, it is convenient to look for
vitamin D deﬁciency in CLE, although further
research is necessary to demonstrate the beneﬁts
of correcting vitamin D status in these patients.
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